Scopolamine Patch Use in 14-Year-Olds
The scopolamine transdermal patch is FDA-approved only for adults and should not be used in a 14-year-old patient for motion sickness prevention, as pediatric safety and efficacy have not been established. 1
FDA Labeling and Age Restrictions
- The FDA-approved indication for scopolamine transdermal system explicitly states it is indicated "in adults" for prevention of nausea and vomiting associated with motion sickness and post-operative nausea and vomiting 1
- All clinical efficacy studies supporting FDA approval were conducted exclusively in adult subjects—195 adult subjects for motion sickness prevention and 168 adult female patients for post-operative nausea and vomiting 1
- The FDA label contains no pediatric dosing information, safety data, or efficacy data for patients under 18 years of age 1
Clinical Evidence Limitations
- The systematic reviews examining scopolamine effectiveness (1025 subjects across 14 studies) do not provide specific data on pediatric populations or adolescents 2
- Research studies evaluating transdermal scopolamine have focused on adult populations without establishing appropriate dosing or safety profiles for children or adolescents 3, 4
Important Safety Consideration for Adolescents
- A case report specifically documented a 14-year-old boy who developed unilateral fixed and dilated pupil (anisocoria) from transdermal scopolamine, initially mistaken for advancing central nervous system infection, highlighting the potential for serious adverse effects and diagnostic confusion in this age group 5
- Anticholinergic side effects including dry mouth, drowsiness, impaired visual accommodation, blurred vision, and mydriasis are common with scopolamine and may be particularly problematic in adolescents 3, 4
Alternative Approaches for Motion Sickness in Adolescents
- Consider antihistamines such as dimenhydrinate or meclizine, which have established pediatric use and safety profiles for motion sickness prevention 6, 2
- Behavioral interventions and complementary therapies may be appropriate first-line options before pharmacological treatment in this age group 6
Critical Caveat
- Off-label use of scopolamine patches in pediatric patients lacks supporting clinical study data and carries unknown risks in this population, making it inappropriate for routine use in a 14-year-old 1